Thromboembolic events with recombinant activated factor vii in spontaneous intracerebral hemorrhage: Results from the factor seven for acute hemorrhagic stroke (FAST) trial

Stroke

Volumn 41, Issue 1, 2010, Pages 48-53

  Diringer, Michael N ^a   Skolnick, Brett E ^b   Mayer, Stephan A ^c   Steiner, Thorsten ^d   Davis, Stephen M ^e   Brun, Nikolai C ^f   Broderick, Joseph P ^g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVO NORDISK INC   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f NOVO NORDISK A S   (Denmark)

^g UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Clinical trials; Data Monitoring Committee; Intracerebral hemorrhage (ICH); Myocardial ischemia; Recombinant activated factor VII (rFVIIa); Thromboembolic events

Indexed keywords

ANTITHROMBOCYTIC AGENT; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TROPONIN I;

AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ELECTROCARDIOGRAPHY; EUROPEAN AMERICAN; FEMALE; GENDER; GLASGOW COMA SCALE; GROUPS BY AGE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; INTRACARDIAC THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

AGED; CEREBRAL HEMORRHAGE; FACTOR VIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOEMBOLISM;

EID: 74049133941     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.561712     Document Type: Article

References (12)

1. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thrombo-embolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-298.
2. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352:777-785.
3. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Broderick JP. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke. 2008;39:850-856.
4. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis SM, Diringer MN, Skolnick BE, Steiner T; FAST Trial Investigators. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008;358:2127-2137.
5. Broderick JP, Adams HP Jr, Barsan W, Feinberg W, Feldmann E, Grotta J, Kase C, Krieger D, Mayberg M, Tilley B, Zabramski JM, Zuccarello M. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1999;30:905-915.
6. Hardy JF, Belisle S, Van der Linden P. Efficacy and safety of recom-binant activated factor VII to control bleeding in nonhemophiliac patients: a review of 17 randomized controlled trials. Ann Thorac Surg. 2008;86:1038-1048.
7. Hsia CC, Chin-Yee IH, McAlister VC. Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg. 2008;248:61-68.
8. Ranucci M, Isgro G, Soro G, Conti D, De, Toffol B. Efficacy and safety of recombinant activated factor VII in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg. 2008;143:296-304.
9. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, Axelsen M, Kluger Y; NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8-15.
10. Bosch J, Thabut D, Bendtsen F, D'Amico G, Albillos A, Gonzalez Abraldes J, Fabricius S, Erhardtsen E, de Franchis R; European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123-1130.
11. Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, D'Amico G, Lebrec D, de Franchis R, Fabricius S, Cai Y, Bendtsen F; International Study Group on rFVIIa in UGI Hemorrhage. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology. 2008;47:1604-1614.
12. Friederich PW, Levi M, Bauer KA, Vlasuk GP, Rote WE, Breederveld D, Keller T, Spataro M, Barzegar S, Büller HR. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation. 2001;103:2555-2559.